Related Experiment Videos
Expression of O6-methylguanine-DNA methyltransferase in six human medulloblastoma cell lines
X M He1, L E Ostrowski, M A von Wronski
1Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710.
Abstract:
Six well characterized human medulloblastoma cell lines (D283 Med, Daoy, D341 Med, D384 Med, D425 Med, and D458 Med) were examined for the expression of O6-methylguanine-DNA methyltransferase (MGMT) by activity and Western and Northern blot analysis. High levels of MGMT activity were present in D283 Med, Daoy, D341 Med, and D384 Med (1.36, 0.80, 1.68, and 1.62 pmol/mg of protein, respectively), but negligible MGMT activity was detected in D425 Med and D458 Med (0.06 and 0.05 pmol/mg of protein, respectively), which were derived separately at different times from the same patient. The presence of MGMT protein and its transcript was demonstrated in D283 Med, Daoy, D341 Med, and D384 Med, but both the protein and the mRNA were undetectable in D425 Med and D458 Med. Nevertheless, all six cell lines contained an apparently unaltered MGMT gene, as determined by Southern blot analysis. The absence of MGMT activity in D425 Med and D458 Med is likely due to the absence of the protein, resulting from a lack of transcription of the MGMT gene. The varying levels of expression of MGMT in medulloblastoma cells found in this study should provide a molecular basis for drug design and selection in chemotherapy of this tumor.
Insights
Six human medulloblastoma cell lines showed varying expression of O6-methylguanine-DNA methyltransferase (MGMT). This difference in MGMT activity, protein, and mRNA levels, despite unaltered genes, impacts chemotherapy drug selection for this brain tumor.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Medulloblastoma is a common pediatric brain tumor.
- O6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair protein implicated in chemoresistance.
- Understanding MGMT expression in medulloblastoma is crucial for effective treatment strategies.
Purpose of the Study:
- To investigate the expression levels of MGMT in human medulloblastoma cell lines.
- To determine if genetic alterations in the MGMT gene correlate with its expression.
- To establish a molecular basis for tailoring chemotherapy for medulloblastoma.
Main Methods:
- Analysis of MGMT activity using biochemical assays.
- Detection of MGMT protein via Western blot.
- Assessment of MGMT mRNA levels through Northern blot analysis.
- Evaluation of MGMT gene integrity using Southern blot analysis.
Main Results:
- Four cell lines (D283 Med, Daoy, D341 Med, D384 Med) exhibited high MGMT activity, protein, and mRNA.
- Two cell lines (D425 Med, D458 Med) showed negligible MGMT activity, protein, and mRNA.
- All six cell lines possessed an unaltered MGMT gene, indicating transcriptional regulation is key.
- D425 Med and D458 Med, derived from the same patient, displayed a lack of MGMT expression.
Conclusions:
- Medulloblastoma cell lines exhibit differential MGMT expression.
- MGMT expression is regulated at the transcriptional level, not by gene mutation.
- Variations in MGMT expression provide a rationale for personalized drug selection in medulloblastoma chemotherapy.